RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Immunovia AB (publ) EBIT 2024

Immunovia AB (publ) EBIT

180.79 M SEK

Immunovia AB (publ) Dividend yield

Ticker

IMMNOV.ST

ISIN

SE0006091997

WKN

A2AG0F

In 2024, Immunovia AB (publ)'s EBIT was 180.79 M SEK, a -160.95% increase from the -296.62 M SEK EBIT recorded in the previous year.

The Immunovia AB (publ) EBIT history

YEAREBIT (undefined SEK)
2026e-67.84
2025e-50.77
2024e180.79
2023-296.62
2022-191.21
2021-166.74
2020-134.68
2019-114.35
2018-88.23
2017-45.58
2016-14.99
2015-7.42
2014-8.96
2013-1.61

Immunovia AB (publ) Aktienanalyse

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a leading company in cancer diagnostics based in Lund, Sweden. Founded in 2007 by a group of scientists and entrepreneurs, the company specializes in the development, production, and marketing of diagnostic tests. Immunovia aims to develop innovative and reliable methods for early cancer detection to improve the progress and quality of life for cancer patients. The company's business model is based on research and development of state-of-the-art diagnostic tests, which are distributed worldwide through a network of partners. Immunovia collaborates closely with academic institutions, medical centers, and hospitals to promote research activities and conduct clinical studies. The company's goal is to develop biomarker-based tests for early cancer detection to increase patient survival rates. Immunovia operates in various fields, including pancreatic cancer diagnosis, colorectal cancer diagnosis, lupus diagnosis, and general cancer diagnostics. The company has developed products based on its diagnostic tests, such as the IMMray™ PanCan-d Test for pancreatic cancer diagnosis, IMMray™ Colon Test for colorectal cancer diagnosis, IMMray™ Lupus Test for lupus diagnosis, and IMMray™ Cancer-Screening Test for general cancer diagnostics. Immunovia actively collaborates with various partners, including strategic partnerships with leading biotechnology and pharmaceutical actors, to develop advanced diagnostic products. The company also has a strong financial base to fund its research activities and clinical studies. Overall, Immunovia is dedicated to developing innovative diagnostic tests for early cancer detection and is considered one of the leading players in the cancer diagnostics industry. Immunovia AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Immunovia AB (publ)'s EBIT

Immunovia AB (publ)'s Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Immunovia AB (publ)'s EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Immunovia AB (publ)'s EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Immunovia AB (publ)’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Immunovia AB (publ) Stock

How much did Immunovia AB (publ) achieve in EBIT for the current year?

In the current year, Immunovia AB (publ) has achieved an EBIT of 180.79 M SEK.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Immunovia AB (publ).

How has the EBIT of Immunovia AB (publ) developed in recent years?

The EBIT of Immunovia AB (publ) has increased by -160.951% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Immunovia AB (publ)?

The EBIT of Immunovia AB (publ) is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Immunovia AB (publ) pay?

Over the past 12 months, Immunovia AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovia AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Immunovia AB (publ)?

The current dividend yield of Immunovia AB (publ) is .

When does Immunovia AB (publ) pay dividends?

Immunovia AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunovia AB (publ)?

Immunovia AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Immunovia AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunovia AB (publ) located?

Immunovia AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunovia AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunovia AB (publ) from 5/31/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did Immunovia AB (publ) pay the last dividend?

The last dividend was paid out on 5/31/2024.

What was the dividend of Immunovia AB (publ) in the year 2023?

In the year 2023, Immunovia AB (publ) distributed 0 SEK as dividends.

In which currency does Immunovia AB (publ) pay out the dividend?

The dividends of Immunovia AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunovia AB (publ)

Our stock analysis for Immunovia AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovia AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.